Literature DB >> 2997292

Inhibition of parathyroid hormone secretion and parathyroid hormone-independent diminution of tubular calcium reabsorption by WR-2721, a unique hypocalcemic agent.

S Hirschel-Scholz, J Caverzasio, J P Bonjour.   

Abstract

Hypocalcemia has been observed in patients receiving WR-2721 [S-,2-(3-aminopropylamino)-, ethylphosphorothioic acid]. WR-2721 is a compound that, after being dephosphorylated, provides protection of normal tissues against radio- and chemotherapy. The hypocalcemic response was accompanied by a decrease in the plasma level of parathyroid hormone (PTH) and by hypomagnesemia. Our present studies in rats on the mechanism of the hypocalcemic effect of WR-2721 indicate that: (a) The phosphorylated and dephosphorylated form of WR-2721 induced an equal dose-dependent decrement in plasma calcium. (b) In intact rats a maximal hypocalcemic dose of WR-2721 reduced urinary cyclic AMP excretion from 70.5 +/- 6.3 to 38.2 +/- 3.1 pmol/ml glomerular filtration rate (GFR), a level comparable to that observed (35.9 +/- 5.2 pmol/ml GFR) in thyroparathyroidectomized (TPTX) rats. (c) WR-2721 given to TPTX rats did not significantly interfere with the calcemic effect of bovine PTH 1-34 infused at 2.5 IU/h. Likewise, the drug did not impair the PTH actions on the renal Ca and inorganic phosphate (Pi) handling, and on the urine cyclic AMP excretion. (d) In TPTX rats made normocalcemic by low Pi diet, the hypocalcemic effect of WR-2721 was only about 25% of that observed in intact animals. However, it was associated with increased urine Ca per milliliter GFR, indicating a PTH-independent inhibitory effect on tubular Ca reabsorption. (e) In WR-2721-treated intact rats, prevention of hypomagnesemia by infusing magnesium chloride did not reduce hypocalcemia. In conclusion, the hypocalcemic effect of WR-2721 is not dependent upon the presence of a phosphate group in the molecule and is not causally related to hypomagnesemia. WR-2721 appears to be a unique hypocalcemic pharmacologic agent with strong inhibitory activity on PTH secretion and additional PTH-independent action on renal Ca reabsorption.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2997292      PMCID: PMC424224          DOI: 10.1172/JCI112178

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  15 in total

1.  Biological factors affecting the radioprotective efficiency of S-2-[2-aminopropylamino] ethylphosphorothioic acid (WR-2721). LD50(3)) doses.

Authors:  J M Yuhas
Journal:  Radiat Res       Date:  1970-12       Impact factor: 2.841

2.  Cimetidine in primary hyperparathyroidism.

Authors:  S Ljunghall; G Akerström; C Rudberg; L Wide; H Johansson
Journal:  Lancet       Date:  1980-08-30       Impact factor: 79.321

3.  Propranolol in primary hyperparathyroidism.

Authors:  J P Monson; M Beer; B J Boucher; R D Cohen
Journal:  Lancet       Date:  1979-04-21       Impact factor: 79.321

4.  Effect of 1,25-dihydroxyvitamin D3 on the renal handling of Pi in thyroparathyroidectomized rats.

Authors:  J P Bonjour; C Preston; H Fleisch
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

5.  Suppression of parathyroid secretion after administration of WR-2721 in a patient with parathyroid carcinoma.

Authors:  S Hirschel-Scholz; A Jung; J A Fischer; U Trechsel; J P Bonjour
Journal:  Clin Endocrinol (Oxf)       Date:  1985-09       Impact factor: 3.478

6.  The role of WR-2721 in radiotherapy and/or chemotherapy.

Authors:  J M Yuhas; J M Spellman; F Culo
Journal:  Cancer Clin Trials       Date:  1980

7.  Parathyroid hormone secretion: effect of beta-adrenergic blockade before and after surgery for primary hyperparathyroidism.

Authors:  N M Vora; S C Kukreja; G A Williams; G K Hargis
Journal:  J Clin Endocrinol Metab       Date:  1981-09       Impact factor: 5.958

8.  Renal handling of calcium: influence of parathyroid hormone and 1,25-dihydroxyvitamin D3.

Authors:  K Hugi; J P Bonjour; H Fleisch
Journal:  Am J Physiol       Date:  1979-04

9.  Failure of cimetidine to affect calcium homeostasis in familial primary hyperparathyroidism (multiple endocrine neoplasia, type 1).

Authors:  M F Robinson; A B Hayles; H Heath
Journal:  J Clin Endocrinol Metab       Date:  1980-10       Impact factor: 5.958

Review 10.  The medical management of primary hyperparathyroidism.

Authors:  J P Bilezikian
Journal:  Ann Intern Med       Date:  1982-02       Impact factor: 25.391

View more
  3 in total

1.  Prevention of parathyroid hormone-dependent nephrocalcinosis by chronic administration of the organic phosphorothioate WR-2721.

Authors:  S Hirschel-Scholz; J Caverzasio; J P Bonjour
Journal:  Calcif Tissue Int       Date:  1987-02       Impact factor: 4.333

2.  Normalization of hypercalcemia associated with a decrease in renal calcium reabsorption in Leydig cell tumor-bearing rats treated with WR-2721.

Authors:  S Hirschel-Scholz; J Caverzasio; R Rizzoli; J P Bonjour
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

3.  Beneficial effect of the oxygen free radical scavenger amifostine (WR-2721) on spinal cord ischemia/reperfusion injury in rabbits.

Authors:  Fany Chronidou; Efstratios Apostolakis; Ioannis Papapostolou; Konstantinos Grintzalis; Christos D Georgiou; Efstratios N Koletsis; Menelaos Karanikolas; Panagiotis Papathanasopoulos; Dimitrios Dougenis
Journal:  J Cardiothorac Surg       Date:  2009-09-17       Impact factor: 1.637

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.